The invention discloses the use of adenosine receptor agonists, preferably A3 receptor agonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders assocd. with underexpression of HIF-1 and/or decreased HIF-1 activity (e.g., ischemic related disorders). The methods of the invention are directed to methods of reducing tissue damage (e.g., substantially preventing tissue damage, inducing tissue protection) resulting from ischemia or hypoxia. The invention provides methods for treating, preventing and/or ameliorating one or more symptoms of hypoxic or HIF-1-related disorders by administering an A3 receptor agonist either alone or in combination with other agents.
Enhancing treatment of HIF-1-mediated disorders with adenosine A3 receptor agonists.
BOREA, Pier Andrea;BARALDI, Pier Giovanni;MERIGHI, Stefania;
2006
Abstract
The invention discloses the use of adenosine receptor agonists, preferably A3 receptor agonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders assocd. with underexpression of HIF-1 and/or decreased HIF-1 activity (e.g., ischemic related disorders). The methods of the invention are directed to methods of reducing tissue damage (e.g., substantially preventing tissue damage, inducing tissue protection) resulting from ischemia or hypoxia. The invention provides methods for treating, preventing and/or ameliorating one or more symptoms of hypoxic or HIF-1-related disorders by administering an A3 receptor agonist either alone or in combination with other agents.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
